Imaging Endpoints Highlights Extensive Soft-Tissue Sarcoma Experience

August 19, 2021 – As the largest oncology-focused iCRO, Imaging Endpoints has extensive experience in soft-tissue sarcomas. The company has participated in a large number of multi-national trials, including one of the industry’s largest, performing real-time double reads with adjudication and reporting of the status for progressive (PD) vs. non-progressive (non-PD) disease to sites within 3 business days. To learn more about our oncology services, visit ImagingEndpoints.com.